← Back to headlines
Cytokinetics Outlines 2026 Operating Expenses and MYQORZO Germany Launch
Cytokinetics has projected its operating expenses to be between $830 million and $870 million for 2026, while also progressing with the launch of its product MYQORZO in Germany.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
